Automotive applications of thermoplastic vulcanizates

Thermoplastic vulcanizates (TPVs) are special classes of thermoplastic elastomers, in which dynamic vulcanization of the rubber phase takes place during melt mixing with a semicrystalline thermoplastic matrix phase at elevated temperature. This review article focus on the different types of thermoplastic vulcanizates (TPVs) from various elastomer and thermoplastic blends that are suitable for the automotive applications purpose. A detailed study of the various TPVs based on polypropylene-ethylene propylene diene rubber (PP-EPDM) and polypropylene-ethylene α-olefin has been focused and their application in the automobile sector has been summarized. Most of the commercially available TPVs are PP-EPDM based. Limited applications of that TPVs in high heat and oil resistant application purposes requires new generation of TPVs. High performance TPVs or super TPVs are new generation TPVs that exhibit high heat resistance as well as excellent oil resistance property suitable for automotive under-the-hood applications. Therefore TPVs based on XNBR-PA12, HNBR-PA12 and FKM-PA6 system has also been explored in details in this study and the possibility of the use of those TPV system has been focused for the high temperature application purpose in the automobile sector where high and oil resistant application properties is the prime concern

Estimation of Interfacial Shear in Ceramic Composites from Frictional Heating Measurements

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/65508/1/j.1151-2916.1991.tb06846.x.pd

Pharmacoeconomics of obesity in China: a scoping review

Background: With the growing rate of obesity and associated chronic conditions in China, there is a need to assess the health and economic burdens of obesity and examine the effectiveness of pharmaceutical, medical, and comprehensive weight-loss interventions. Areas covered: This article reviewed publications retrieved from PubMed and Google Scholar during 2010–2020 on pharmacoeconomic studies related to overweight and obesity in China. We identified five cost-of-illness studies and four cost-effectiveness analyses of weight-loss interventions, including bariatric surgeries and a comprehensive intervention program. Expert opinion: There is a lack of pharmacoeconomic analyses of obesity in China. Existing studies have often taken the health system perspective without accounting for productivity loss. Cohort studies and studies based on electronic health records or claims data are needed to provide the epidemiologic parameters required for homegrown economic evaluations of the health and economic burdens of obesity in China, as well as the cost-effectiveness of interventions to reduce obesity and its sequela

Origin of Hysteresis Observed During Fatigue of Ceramic-Matrix Composites

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/66076/1/j.1151-2916.1990.tb05239.x.pd

Health care use and costs of adverse drug events emerging from outpatient treatment in Germany: A modelling approach

<p>Abstract</p> <p>Background</p> <p>This study's aim was to develop a first quantification of the frequency and costs of adverse drug events (ADEs) originating in ambulatory medical practice in Germany.</p> <p>Methods</p> <p>The frequencies and costs of ADEs were quantified for a base case, building on an existing cost-of-illness model for ADEs. The model originates from the U.S. health care system, its structure of treatment probabilities linked to ADEs was transferred to Germany. Sensitivity analyses based on values determined from a literature review were used to test the postulated results.</p> <p>Results</p> <p>For Germany, the base case postulated that about 2 million adults ingesting medications have will have an ADE in 2007. Health care costs related to ADEs in this base case totalled 816 million Euros, mean costs per case were 381 Euros. About 58% of costs resulted from hospitalisations, 11% from emergency department visits and 21% from long-term care. Base case estimates of frequency and costs of ADEs were lower than all estimates of the sensitivity analyses.</p> <p>Discussion</p> <p>The postulated frequency and costs of ADEs illustrate the possible size of the health problems and economic burden related to ADEs in Germany. The validity of the U.S. treatment structure used remains to be determined for Germany. The sensitivity analysis used assumptions from different studies and thus further quantified the information gap in Germany regarding ADEs.</p> <p>Conclusions</p> <p>This study found costs of ADEs in the ambulatory setting in Germany to be significant. Due to data scarcity, results are only a rough indication.</p

Thermomechanical Fatigue Behavior of a Silicon Carbide Fiber-Reinforced Calcium Aluminosilicate Composite

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/65874/1/j.1151-2916.1993.tb04022.x.pd

Frictional heating in a unidirectional fibre-reinforced ceramic composite

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/43020/1/10855_2004_Article_BF00720776.pd

Percentage of Patients with Preventable Adverse Drug Reactions and Preventability of Adverse Drug Reactions – A Meta-Analysis

BACKGROUND: Numerous observational studies suggest that preventable adverse drug reactions are a significant burden in healthcare, but no meta-analysis using a standardised definition for adverse drug reactions exists. The aim of the study was to estimate the percentage of patients with preventable adverse drug reactions and the preventability of adverse drug reactions in adult outpatients and inpatients. METHODS: Studies were identified through searching Cochrane, CINAHL, EMBASE, IPA, Medline, PsycINFO and Web of Science in September 2010, and by hand searching the reference lists of identified papers. Original peer-reviewed research articles in English that defined adverse drug reactions according to WHO's or similar definition and assessed preventability were included. Disease or treatment specific studies were excluded. Meta-analysis on the percentage of patients with preventable adverse drug reactions and the preventability of adverse drug reactions was conducted. RESULTS: Data were analysed from 16 original studies on outpatients with 48797 emergency visits or hospital admissions and from 8 studies involving 24128 inpatients. No studies in primary care were identified. Among adult outpatients, 2.0% (95% confidence interval (CI): 1.2-3.2%) had preventable adverse drug reactions and 52% (95% CI: 42-62%) of adverse drug reactions were preventable. Among inpatients, 1.6% (95% CI: 0.1-51%) had preventable adverse drug reactions and 45% (95% CI: 33-58%) of adverse drug reactions were preventable. CONCLUSIONS: This meta-analysis corroborates that preventable adverse drug reactions are a significant burden to healthcare among adult outpatients. Among both outpatients and inpatients, approximately half of adverse drug reactions are preventable, demonstrating that further evidence on prevention strategies is required. The percentage of patients with preventable adverse drug reactions among inpatients and in primary care is largely unknown and should be investigated in future research